GAMMA Investing’s Neuropace NPCE Stock Holding History

GAMMA Investing’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$41	Buy	+3	New	+$44	﹤0.01%	4313
2026 Q1	–	Sell	-9	Closed	-$139	–	4198
2025 Q4	$139	Buy	+9	New	+$120	﹤0.01%	4040
2025 Q3	–	Sell	-402	Closed	-$4.48K	–	3897
2025 Q2	$4.48K	Buy	402 +50	+14%	+$625	﹤0.01%	3168
2025 Q1	$4.33K	Buy	+352	New	+$4.41K	﹤0.01%	3140

Other funds holding NPCE

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's NPCE Position: Q3 2026 in Review

GAMMA Investing opened a new position in Neuropace (NPCE) in Q3 2026: 3 shares worth $41. The stake represents ﹤0.01% of the portfolio and ranks #4313 among its holdings. This is a return to the name: GAMMA Investing previously reported a position in NPCE as recently as Q4 2025.

GAMMA Investing first reported a position in NPCE in Q1 2025 and has held it in 4 quarters since. The position peaked at $4.48K in Q2 2025. 3 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

GAMMA Investing held 3 shares of Neuropace worth $41 as of Q3 2026.
Neuropace was a new GAMMA Investing position in Q3 2026.
Neuropace made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4313 holding.
GAMMA Investing first reported a position in Neuropace in Q1 2025 and has held it in 4 quarters since.
GAMMA Investing's Neuropace position peaked at $4.48K in Q2 2025.
3 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.